Effectiveness of the Cytokine Hemadsorption on Sepsis

Effectiveness of the Cytokine Hemadsorption on the Clinical Progression and Mortality of Intensive Care Patients With Sepsis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05057455

Enrollment

Registered

2021-09-27

Start date

2020-01-01

Completion date

2021-02-15

Last updated

2021-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interleukin-6

Brief summary

In this prospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Interventions

PROCEDUREcytokine hemadsorption

the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* the patients were the available data of clinical and laboratory diagnosis of sepsis and septic shock * detection of gram-negative bacterial agent in blood or sputum culture. * patients who had the shock symptoms such as hypotension, tachycardia or fever during the course of sepsis.

Exclusion criteria

* had uncontrolled hemorrhage, * diagnosed with cardiac failure at stage 4 or renal failure at stage 4 or hepatic liver failure at stage 4 * cancer at the end stage or admitted with acute coronary syndrome.

Design outcomes

Primary

Measure	Time frame	Description
IL-6	1 YEARS	levels of IL-6

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026